Home・Список акций・Krystal Biotech Inc

Krystal Biotech Inc

Закрыт

СекторЗдравоохранение

323.48 0.42

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

315.04

Макс.

328

Ключевые показатели
By Trading Economics
Доход	-1.2M 55M
Продажи	2.9M 119M
P/E Средняя по отрасли	45.697 68.51
Прибыль на акцию	1.79
Рентабельность продаж	45.938
Сотрудники	295
EBITDA	2.9M 66M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+24.15% upside

Дивиденды
By Acuity
Следующий отчет о доходах	2 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-1.1B 9.3B
Предыдущая цена открытия	323.06
Предыдущая цена закрытия	323.48

Новостные настроения

By Acuity

14%

86%

33 / 340 Рейтинг в Healthcare

Krystal Biotech Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 20:04 UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

3 авг. 2026 г., 23:06 UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

31 июл. 2026 г., 23:06 UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

30 июл. 2026 г., 19:39 UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

29 июл. 2026 г., 20:04 UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

28 июл. 2026 г., 20:03 UTC

Event

Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

27 июл. 2026 г., 22:02 UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

24 июл. 2026 г., 19:11 UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

23 июл. 2026 г., 10:01 UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

22 июл. 2026 г., 19:26 UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

21 июл. 2026 г., 18:36 UTC

News

Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

20 июл. 2026 г., 21:21 UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Сравнение c конкурентами

Изменение цены

Krystal Biotech Inc Прогноз

Целевая цена

By TipRanks

24.15% рост

Прогноз на 12 месяцев

Средняя 403.2 USD 24.15%

Максимум 474 USD

Минимум 361 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Krystal Biotech Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

Покупка

Удержание

Продажа

Основано на мнении 6 аналитиков, присваивавших рейтинги акциям Krystal Biotech Inc – Данные за последние 3 месяца.

Настроения

By Acuity

33 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.